Across TCGA pan-cancer cohorts, SPIRE2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPIRE2 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in mesothelioma (MESO), where higher SPIRE2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPIRE2 expression acts as an unfavorable survival marker.
MESO, BLCA, and STAD are the cancer types where SPIRE2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.